Speaker Profile
PMWC PIONEER AWARD
Ph.D., Picower Professor of Neuroscience, MIT
Biography
Professor Li-Huei Tsai is the Picower Professor of Neuroscience at the Department of Brain and Cognitive Sciences and a member of the Picower Institute for Learning and Memory, at the Massachusetts Institute of Technology. She pioneered the use of non-invasive sensory stimulation to treat Alzheimer’s disease and other neurological disorders. Tsai is a Fellow of the American Association for the Advancement of Science, a Fellow of the National Academy of Inventors, a Member of the National Academy of Medicine, an Academician of the Academia Sinica in Taiwan, and a Member of the American Academy of Arts and Sciences. She is a recipient of the Mika Salpeter Lifetime Achievement Award, the 2018 Hans Wigzell Research Foundation Science Prize for her research on Alzheimer’s disease, and 2025 Distinguished Lecturer for Parkinson’s Disease Research, Helis Medical Research Foundations. In 2022 she was named a Visiting Professor of the Vallee Foundation.
Talk
Sensory Gamma Stimulation in Neuroprotection/Treating Alzheimer’s
Gamma oscillations (30–80 Hz) support cognition and are disrupted in Alzheimer’s disease. We developed GENUS, delivering 40 Hz light and sound, which increases gamma power, reduces pathology, and improves cognition in mouse models. GENUS also alters glia and vasculature, enhancing glymphatic clearance via cholinergic and neuropeptide signaling underlying neuroprotection mechanisms.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Ira Mellman, Medici Therapeutics
PMWC Award Ceremony
• Jedd D. Wolchok, Weill Cornell Medicine
• Suzanne Topalian, Johns Hopkins
• Levi Garraway, Roche
Keynote: Future Breakthroughs in Immuno-Oncology: New Targets, Modalities & Combinations
• Levi Garraway, Roche
Checkpoint 2.0 in Practice: PD-1+VEGF Wins, Resistance Salvage & Biomarker Gates
• Chair: Anne Kasmar, Parexel
• Jedd D. Wolchok, Weill Cornell Medicine
• Roy S. Herbst, Yale
• Nathan Fowler, BostonGene
Immunotherapy with Personalized Cancer Vaccines: Who, When, How Fast?
• Chair: Suzanne Topalian, Johns Hopkins
• Tal Zaks, Orbimed
• Lelia Delamarre, Genentech
The Next Era: Neutralizing On-Target, Off-Tumor Effects by Turning Cancer Against Itself
• Cyriac Roeding, Earli
Fireside Chat: Immune Tolerance to Cure, A Conversation With...
• Lee Hood, Institute for Systems Biology
• Mary E. Brunkow, Institute for Systems Biology
ADCs in the Checkpoint Era: Who Benefits, What to Combine, What to Avoid
• Chair: Shreya Badhrinarayanan, Pfizer
• Gerold Meinhardt, Daiichi Sankyo
• Vadim Koshkin, UCSF
Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
• Janet Xiao, Morrison & Foerster LLP
Targeting the Tumor Microenvironment (TME) in Practice: Biomarkers & Combos
• Chair: Ira Mellman, Medici Therapeutics
• Dmitry Gabrilovich, AstraZeneca
• Jennifer Mataraza, Novartis
• Nathan Fowler, BostonGene
• Christine Moussion, Genentech
Future Breakthroughs in TME Reprogramming: New Modalities, Smarter Delivery & Overcoming Resistance
• David Kirn, ReIGNITE
Radiopharmaceutical Therapy: New Targets, Isotopes, and Challenges
• Chair: William Oh, Yale
• Munir Ghesani, United Theranostics
• Sandy Srinivas, Stanford
• Anna Karmann, AdvanCell
